COVID-19: an update on diagnostic and therapeutic approaches

키워드

참고문헌 (43)

1. "World Health Organization" (2020)[URL]
2. Balachandar V, "COVID-19: A promising cure for the global panic", Sci Total Environ (2020)
3. Zheng F, "Clinical characteristics of 161 cases of corona virus disease 2019(COVID-19)in Changsha", Eur Rev Med Pharmacol Sci, 24, pp.3404~3410 (2020)
4. Balachandar V, "COVID-19 : Emerging protective measures", Eur Rev Med Pharmaco, 24, pp.3422~3425 (2020)
5. Rothe C, "Transmission of 2019-nCoV infection from an asymptomatic contact in Germany", N Engl J Med, 382, pp.970~971 (2020)
6. Callaway E, "China coronavirus : six questions scientists are asking", Nature, 577, pp.605~607 (2020)
7. Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, 395, pp.497~506 (2020)
8. "Interim guidelines for collecting, handling, and testing clinical specimens from persons for coronavirus disease 2019 (COVID-19)" (2020)[URL]
9. "Advice on the use of point-of-care immunodiagnostic tests for COVID-19" (2020)[URL]
10. "Indian Council of Medical Research (ICMR)" (2020)[URL]
11. "Coronavirus disease (COVID-19) technical guidance: Laboratory testing for 2019-nCoV in humans" (2020)[URL]
12. Cao Y, "Imaging and clinical features of patients with 2019 novel coronavirus SARSCoV‐2: a systematic review and meta‐analysis", J Med Virol (2020)
13. Zhou F, "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China : a retrospective cohort study", Lancet, 395, pp.1054~1062 (2020)
14. Cao J, "Clinical features and short-term outcomes of 102 patients with corona virus disease 2019 in Wuhan, China", Clin Infect Dis (2020)
15. "“Solidarity”clinical trial for COVID-19 treatments" (2020)[URL]
16. Stebbing J, "COVID-19 : combining antiviral and anti-inflammatory treatments", Lancet Infect Dis, 20, pp.400~402 (2020)
18. Plantone D, "Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic and neurological diseases : A Mini-Review", Clin Drug Investig, 38, pp.653~671 (2018)
19. Yan Y, "Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model", Cell Res, 23, pp.300~302 (2013)
20. Li C, "Chloroquine, a FDA-approved drug, prevents Zika virus infection and its associated congenital microcephaly in mice", EBioMedicine, 24, pp.189~194 (2017)
21. Shiryaev SA, "Repurposing of the anti-malaria drug chloroquine for Zika virus treatment and prophylaxis", Sci Rep, 7, pp.15771~ (2017)
22. Yao X, "In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)", Clin Infect Dis (2020)
23. Gao J, "Breakthrough : chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies", Biosci Trends, 14, pp.72~73 (2020)
24. Savarino A, "New insights into the antiviral effects of chloroquine", Lancet Infect Dis, 6, pp.67~69 (2006)
25. Ducharme J, "Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements", Clin Pharmacokinet, 31, pp.257~274 (1996)
26. Wang M, "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus(2019-nCoV)in vitro", Cell Res, 30, pp.269~271 (2020)
27. Vincent MJ, "Chloroquine is a potent inhibitor of SARS coronavirus infection and spread", Virol J, 2, pp.69~ (2005)
28. Devaux CA, "New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?", Int J Antimicrob Agents (2020)
29. Savarino A., "Effectd of chloroquine on viral infections : an old drug against today’s diseases", Lancet Infect Dis, 3, pp.722~727 (2003)
30. Wang LS, "A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence", Int J Antimicrob Agents (2020)
31. Gautret P, "Hydroxychloroquine and azithromycin as a treatment of COVID-19:results of an open-label non-randomized clinical trial", Int J Antimicrob Agents (2020)
32. Luke T, "Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?", Ann Intern Med, 145, pp.599~609 (2006)
33. Van Griensven J, "Evaluation of convalescent plasma for Ebola virus disease in Guinea", N Engl J Med, 374, pp.33~42 (2016)
34. Zhou B, "Treatment with convalescent plasma for influenza A(H5N1)infection", N Engl J Med, 357, pp.1450~1451 (2007)
35. Mair-Jenkins J, "The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology : a systematic review and exploratory meta-analysis", J Infect Dis, 211, pp.80~90 (2015)
36. Hung IF, "Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A(H1N1)2009 virus infection", Clin Infect Dis, 52, pp.447~456 (2011)
37. Cheng Z, "Clinical features and chest CT manifestations of coronavirus disease 2019(COVID-19) in a single-center study in Shanghai, China", Am J Roentgenol (2020)
38. Ko JH, "Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection : a single centre experience", Antivir ther, 23, pp.617~622 (2018)
39. Lee PI, "Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV", J Microbiol Immunol Infect (2020)
40. Chen L, "Convalescent plasma as a potential therapy for COVID-19", Lancet Infect Dis, 20, pp.398~400 (2020)
41. Bobati SS, "Therapeutic plasma exchange-an emerging treatment modality in patients with neurologic and non-neurologic diseases", J Clin Diagn Res, 11, pp.EC35~EC37 (2017)
42. Duan K, "Effectiveness of convalescent plasma therapy in severe COVID-19 patients", Proc Natl Acad Sci U S A (2020)
43. Liu J, "Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro", Cell Discov, 6, pp.16~ (2020)

관련 논문AI추천